Ozempic, the injectable drug already used to treat type 2 diabetes and widely prescribed for weight loss, may also lower the risk of broken bones, according to a new study reported by U.S. News and World Report.
The drug's active ingredient, semaglutide, belongs to a class of medications known as GLP-1 receptor agonists. These drugs work by mimicking a hormone that regulates blood sugar and appetite. Ozempic and similar medications have drawn significant research attention in recent years as scientists continue to examine their effects beyond blood sugar control and weight reduction.
The study adds to a growing body of research exploring whether semaglutide has broader protective effects on the body. Bone fractures are a significant health concern, particularly for older adults and people with diabetes, who already face elevated fracture risk compared to the general population.
The findings were described as notable given that some earlier concerns had been raised about whether rapid weight loss from GLP-1 drugs might negatively affect bone density. Weight loss in general can sometimes lead to reductions in bone mass, which can increase fracture risk over time. The new study's suggestion that semaglutide may instead reduce fracture risk runs counter to some of those earlier worries.
U.S. News and World Report did not detail the full methodology of the study in its coverage, including the size of the study population, how long participants were followed, or whether the findings have been published in a peer-reviewed journal. Those details would be relevant for understanding how much weight to give the results.
Semaglutide is sold under several brand names, including Ozempic for diabetes and Wegovy for weight management. Both have seen high demand in recent years, leading to shortages in multiple countries. Researchers continue to study the drug's long-term effects across multiple organ systems, and bone health represents one of several areas under active investigation.
